B. PATIENT INFORMATION LEAFLET

Similar documents
PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

Pyrazinamide 500 mg Tablets (Macleods Pharmaceuticals Ltd), TB243. WHOPAR part 3 April 2014 Section 6 updated: May 2014 PACKAGE LEAFLET.

PATIENT INFORMATION LEAFLET. (company authorized English translation of the Patienteninformation approved by Swissmedic)

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET

Package leaflet: Information for the user. Ebateva 20 mg Orodispersible Tablets. Ebastine

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER. Ethionamide 125 mg Dispersible Tablets 1

Package leaflet: Information for the user

Package leaflet: Information for the patient. Loratadine 10 mg Tablets (loratadine)

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. ILAXTEN 20 MG TABLETS bilastine

WHOPAR Part 3 March Zinc (as sulfate monohydrate) 20 mg Tablets (Macleods Pharmaceuticals Ltd), DI005 PACKAGE LEAFLET.

PATIENT INFORMATION LEAFLET

Package leaflet: Information for the patient. Histaclar 10 mg Film-coated Tablets loratadine

PATIENT INFORMATION LEAFLET

Package leaflet: Information for the patient. SIRTURO 100 mg tablets Bedaquiline

PACKAGE LEAFLET: INFORMATION FOR THE USER Irbea 75 mg film-coated tablets Irbesartan

Package leaflet: Information for the user. Famvir 125, 250 and 500 mg film-coated tablets famciclovir

Package leaflet: Information for the user. Dalmevin 50 mg tablets Vildagliptin

Package leaflet: Information for the user. Flutamid Stada 250 mg tablets Flutamide

Package leaflet: Information for the patient. Valsartan 320 mg Film-coated Tablets valsartan

SINGULAIR JUNIOR 5mg chewable tablets

Package leaflet: Information for the patient. [To be completed nationally] 10 mg film-coated tablets Ebastine

Package leaflet: Information for the user. Omnilax 10 g powder for oral solution, sachet. Macrogol 4000

Package leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride

Patient leaflet: Information for the user. Paracetamol Galpharm 500mg tablets paracetamol

Package leaflet: Information for the user. Entecavir Alvogen 0,5 mg filmomhulde tabletten Entecavir Alvogen 1 mg filmomhulde tabletten Entecavir

PATIENT INFORMATION LEAFLET

Package leaflet: Information for the user. Irprestan 150 mg film-coated tablets. Irprestan 300 mg film-coated tablets irbesartan

Package leaflet: Information for the patient. Bumetanide 1 mg and 5 mg Tablets (bumetanide)

Package leaflet: Information for the patient

XYZAL 5 MG FILM-COATED TABLET

Package leaflet: Information for the user. Cefixime ABR 100 mg/5 ml powder for oral suspension Cefixime

PATIENT INFORMATION LEAFLET

Package leaflet: Information for the user. Tianeptine 12.5 mg Film Coated Tablets (Tianeptine Sodium)

Irbenida 150 mg film-coated tablets; 300 mg film-coated tablets

1. What Solpadol is and what it is used for

Package leaflet: Information for the patient. Dexametason Abcur 4 mg tablets. Dexamethasone

Package leaflet: Information for the patient. Flynise 5 mg Orodispersible Tablets desloratadine

PACKAGE LEAFLET: INFORMATION FOR THE USER. Dantrium 25 mg Capsules / Dantrium 100 mg Capsules Dantrolene sodium

Irbenida H 150mg/12,5mg film-coated tablets

Package leaflet: Information for the user. <PRODUCT NAME> 10 g powder for oral solution in sachet Macrogol 4000

PATIENT INFORMATION LEAFLET

Package leaflet: Information for the patient

What is in this leaflet

Package leaflet: Information for the user. Melatonin Pharma Nord 3 mg, film-coated tablets melatonin

2 What you need to know before you take Naramig

1. WHAT OXCARBAZEPINE IS AND WHAT IT IS USED FOR

PACKAGE LEAFLET: INFORMATION FOR THE USER ZIRPINE 10mg TABLETS Cetirizine dihydrochloride

Package leaflet: Information for the patient

PATIENT INFORMATION LEAFLET. Calcichew* 500 mg Chewable Tablets calcium carbonate

PACKAGE LEAFLET: INFORMATION FOR THE USER

C O N F I D E N T I A L

PATIENT INFORMATION LEAFLET

Sanomigran 500 microgram Tablets and Sanomigran 1.5 mg Tablets

Package leaflet: Information for the patient. Cetirizin Sandoz 10 mg film-coated tablets. cetirizine dihydrochloride

Package leaflet: Information for the user. Fluvastatin

Zinnat can also be used: to treat Lyme disease (an infection spread by parasites called ticks).

Package leaflet: Information for the user

PATIENT INFORMATION LEAFLET

PACKAGE LEAFLET: INFORMATION FOR THE USER. Risedronat Jubilant 5 mg film-coated tablets risedronate sodium

Package leaflet: Information for the user. Levonorgestrel 1.5 mg Tablet. levonorgestrel

PATIENT INFORMATION LEAFLET AMLOC RANGE

NORVASC 5 mg and 10 mg tablets

AVIOMARIN 50 mg tablets

Package leaflet: Information for the user. Burinex 5 mg Tablets bumetanide

PACKAGE LEAFLET: INFORMATION FOR THE USER. XIFAXANTA 200 mg film-coated tablets Rifaximin

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET DYNARB RANGE

Package leaflet: Information for the patient. Clarithromycin Kern Pharma 500 film-coated tablets Clarithromycin

Package Leaflet: Information for the User. Clonamox 125 mg/5 ml Powder for Oral Suspension Clonamox 250 mg/5 ml Powder for Oral Suspension

PACKAGE LEAFLET. Page 1 of 6

Some general information on hepatitis A infection is given at the end of this leaflet.

Package leaflet: Information for the user. Sebivo 600 mg film-coated tablets Telbivudine

PATIENT INFORMATION LEAFLET

PACKAGE LEAFLET: INFORMATION FOR THE USER. Risedronat Jubilant 35 mg film-coated tablets risedronate sodium

Package leaflet: Information for the patient. Vertigon 8 mg Tablets Vertigon 16 mg Tablets (betahistine dihydrochloride)

Package leaflet: Information for the user. Zolpidem Vitabalans 10 mg film-coated tablets zolpidem tartrate

PATIENT INFORMATION LEAFLET TEXAMER

PATIENT INFORMATION LEAFLET

Package leaflet: Information for the user. Ezetimibe STADA 10 mg, tabletten. Ezetimibe

Read this entire leaflet carefully before you start taking DYNA BEZAFIBRATE. If you have further questions, please ask your doctor or your pharmacist.

Zofran tablets contain a medicine called ondansetron. This belongs to a group of medicines called anti-emetics.

Package leaflet: Information for the user. Cinfalair 4 mg chewable tablets montelukast

Package leaflet: Information for the user. Resolor 1 mg film-coated tablets Resolor 2 mg film-coated tablets prucalopride

PACKAGE LEAFLET: INFORMATION FOR THE USER. Cinfalair 4 mg chewable tablets

Package leaflet: Information for the patient. Valsartan 40 mg Film-coated Tablets valsartan

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets

Package leaflet: Information for the patient. Acetylsalicylic acid Bluefish 75 mg tablets Acetylsalicylic acid Bluefish 160 mg tablets

Package leaflet: Information for the User Clarityn 10 mg tablets Loratadine

Package leaflet: Information for the patient. Valotix 500 mg Film-Coated Tablets Valaciclovir

Package leaflet: Information for the user. CYPROSTAT 50 mg tablet cyproterone acetate

Transcription:

B. PATIENT INFORMATION LEAFLET 1

Information for the patient Lumartem DT 1 Artemether/Lumefantrine 20mg/120mg dispersible tablets Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have questions about the medicine, ask your health care provider. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness seem to be the same as yours. - If you get any side effects, talk to your health care provider. This includes unwanted effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Lumartem DT is and what it is used for 2. What you need to know before you take Lumartem DT 3. How to take Lumartem DT 4. Possible side effects 5. How to store Lumartem DT 6. Contents of the pack and other information 1. What Lumartem DT is and what it is used for This medicine is an antimalarial. It is used to treat a certain type of malaria infection in adults and children who weigh at least 5 kg. Lumartem DT contains two antimalarial drugs, artemether and lumefantrine in fixed, which work together to kill the malaria parasite (a tiny organism that is found inside the red blood cells). Your health care provider has found that you have malaria and so has prescribed Lumartem DT. It is indicated only for the treatment of so called uncomplicated malarial attacks due to Plasmodium falciparum (a particular type of malaria parasite) against which the medicine is active. For complete cure it is important that you complete the prescribed as advised by your health care provider. 2. What you need to know before you takelumartem DT Do not take Lumartem DT: - If you are allergic (hypersensitive) to artemether, lumefantrine, or any of the other ingredients of the Lumartem DT listed at the end of this leaflet. - If you have a severe type of malaria infection that affects the brain, or any other severe complications of malaria (for example affecting the lungs or kidneys). - If you have a heart condition, such as changes in the rhythm or rate of the heartbeat, e.g. called prolongation of the QT interval, slow heartbeat, or severe cardiac disease. - If any member of your family (e.g. parents, grandparents, brothers and sisters) has died suddenly due to a heart rate problem or is known to have been born with heart rate problems. 1 Trade names are not prequalified by WHO. This is the National Medicines Regulatory Authority s (NMRA) responsibility. Throughout this WHOPAR the proprietary name is given as an example only. 2

- If you are taking certain medicines (see Taking other medicines ). - If you have low blood levels of electrolytes such as potassium or magnesium. If any of these apply to you, tell your health care provider before taking Lumartem DT. - If you think you may be allergic, ask your health care provider for advice. Warnings and precautions Talk to your health care provider before taking Lumartem DT: - If you have severe liver or kidney problems. Take special care with Lumartem DT: - If your condition worsens, or if you feel too unwell to eat and drink, contact your health care provider immediately. Your health care provider may want to perform a test called an electrocardiogram (ECG) and check the levels of electrolytes, such as potassium and magnesium in your blood before and during treatment. - If you are taking or have taken any other medication for the treatment of malaria, talk to your health care provider, because some of these medicines must not be given together with Lumartem DT. - If you are infected with both, Plasmodium falciparum and Plasmodium vivax, your health care provider will give you another medicine for you to take completing Lumartem DT treatment. Other medicines and Lumartem DT It is important that you tell your health care provider if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. These may affect the action of Lumartem DT, or Lumartem DT may affect their action. Side effects of either medicine may become worse and/or the medicines may become less effective. Especially tell your health care provider if you take or have recently taken: Any other medicines to treat or prevent malaria Medicines for your heart Antipsychotic medicines (for treatment of abnormal condition of the mind) Antidepressants (medication to alleviate mood disorders) Antibiotics Antihistamines (for treatment of, e.g., allergies) Cisapride (a medicine for improving gastric motility) Medicines to treat HIV infection Medicines to treat hepatitis B or hepatitis C infection Medicines against fungal infection Hormonal methods of birth control (for example birth control pills or contraceptive patch) Lumartem DT with food and drink Lumartem DT should be taken with food or a milky drink. Pregnancy, breast-feeding and fertility Pregnancy Lumartem DT can be used during pregnancy. Breast-feeding The actives of Lumartem DT appear in low amounts in human milk, but at therapeutic s no effects on the breast-fed baby are anticipated. Lumartem DT can be used during breast-feeding. Fertility There is no information on the effects of Lumartem DT on fertility in humans. 3

Driving and using machines Lumartem DTmay cause dizziness and fatigue. If you feel dizzy or fatigued while taking Lumartem DT, do not drive and do not use any tools or machines. 3. How to takelumartem DT Lumartem DT should always be taken exactly as described by the health care provider. You should check with your health care provider if you are not sure. Weight range from 5kg up to 15kg From 15kg up to 25kg From 25kg up to 35kg Immediately diagnosis/ onset of symptoms Time Day 1 Day 2 Day 3 8 hours 1 tablet 1 tablet 1 tablet 1 tablet 1 tablet 1 tablet 2 tablets 2 tablets 2 tablets 2 tablets 2 tablets 2 tablets 3 tablets 3 tablets 3 tablets 3 tablets 3 tablets 3 tablets From 35kg (or 12 years of age) 4 tablets 4 tablets 4 tablets 4 tablets 4 tablets 4 tablets The first should be followed by a second 8 hours. The following two days the s should be taken apart. Giving Lumartem DT 1. Take 2 teaspoons (10 ml) of water in a small and clean container and add the required number of tablets. 2. Swirl the container until tablet disperses, and administer the entire mixture immediately. 3. Rinse the container with an additional 10 ml of water and get the child to drink this water. Lumartem DT should be taken with food or a milky drink. If you are unable to tolerate food, Lumartem DT should still be taken, but your body may take up less of the medicine. If you vomit within 1 hour of taking the medication, you should repeat the. If you take more Lumartem DT than you should If you take too many tablets, immediately contact your health care provider or the nearest hospital emergency department for further advice. If you forget to take Lumartem DT Try to make sure that you do not miss any. However, if you do forget a, take the missed as soon as you realise that you have forgotten it. Then take the next the prescribed interval. Do not take a double to make up for a forgotten tablet. Make sure you take all six s of this regimen. 4

If you stop taking Lumartem DT You should keep taking the medicine for as long as your health care provider has ordered, even if you are feeling better. If you stop the medicine too soon, the infection may not be completely cured. Children weighing less than 5 kg Lumartem DT is not for use in these patients. If you have any further questions on the use of this product, ask your health care provider. 4. Possible side effects Like all medicines, Lumartem DT can cause side effects, although not everybody gets them. It is important that you inform the health care provider of any change in your health. The following side effects have been reported in adults and adolescents above 12 years of age using the recommended 6- regimen. A similar side effect profile was reported for children The most commonly reported side effects (greater than 1 in every 10 patients treated) include palpitations, headache, dizziness, nausea, vomiting, abdominal pain, decreased appetite, joint pain, muscle pain, weakness, tiredness, sleep disorders. Commonly (greater than 1 in every 100 patients treated) reported side effects include cough, rash, itching, diarrhoea and involuntary, rhythmic, muscular contractions (clonus). Uncommon side effects (greater than 1 in every 1000 patients treated but less than 1 in 100): alterations to the electrocardiogram (QT-prolongation), lack of voluntary coordination of muscle movements, which may present e.g. as gait disturbance, numbness (hypoesthesia), somnolence, urticaria, blood tests for liver function abnormal. Allergic reactions and anaemia (low red blood cell count) have been reported in patients treated with Lumartem DT tablets. However, frequency estimates for this side effect are not available. Allergic reactions may present with rash, hives, rapid swelling of the face and throat (angioedema). If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your health care provider as soon as possible. Reporting of side effects If you get any side effects,talk to your health care provider. This includes unwanted effects not listed in this leaflet.if available, you can also report side effects directly through the national reporting system. By reporting side effects, you can help provide more information on the safety of this medicine. 5. How to store Lumartem DT Keep this medicine out of the sight and reach of children. Do not use this medicine the expiry date stated on the blister pack and carton EXP. The expiry date refers to the last day of that month. Do not throw away any medicines in waste water or household waste. Ask your health care provider how to throw away medicines you no longer use. These measures will help protect the environment. 5

6. Contents of the pack and other information Lumartem DT is packed in PVC/Aclar/PVC-Alu blister packs. Pack size: Carton containing a blister of 6 tablets. Carton containing a blister of 12 tablets. Carton containing a blister of 18 tablets. Carton containing 30 blisters of 6 tablets each. Carton containing 30 blisters of 12 tablets each. Carton containing 30 blisters of 18 tablets each. What Lumartem DT contains The active substances are artemether and lumefantrine. The other ingredient(s) in Lumartem DT are: Microcrystalline cellulose; croscarmellose sodium; crospovidone; hydroxypropyl methylcellulose; polysorbate 80; colloidal anhydrous silica; saccharin sodium; cherry flavour permaseal (11035-31) and magnesium stearate What Lumartem DT looks like and contents of the pack Lumartem DT is a yellow coloured, circular shaped, flat bevelled, uncoated tablets, debossed with CL on one side and plain on the other side. No score line. Supplier Cipla Ltd Cipla House Peninsula Business Park Ganpatrao Kadam Marg Lower Parel Mumbai: 400013 India Tel: +91 22 24826000 Manufacturer CiplaLimited Unit IV, Plot no. 9 & 10 Pharma Zone, Phase II Indore special economic zone Pithampur (MP) 454775 India For any information about this medicine, contact the supplier: This leaflet was last revised in March 2018 Detailed information on this medicine is available on the World Health Organization (WHO) web site: https://extranet.who.int/prequal/ 6